|
1
|
Jiao Y, Shi C, Edil BH, et al: DAXX/ATRX,
MEN1, and mTOR pathway genes are frequently altered in pancreatic
neuroendocrine tumors. Science. 331:1199–1203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Modlin IM, Lye KD and Kidd M: A 5-decade
analysis of 13,715 carcinoid tumors. Cancer. 97:934–959. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Modlin IM, Oberg K, Chung DC, Jensen RT,
de Herder WW, Thakker RV, Caplin M, Fave G Delle, Kaltsas GA,
Krenning EP, et al: Gastroenteropancreatic neuroendocrine tumours.
Lancet Oncol. 9:61–72. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lawrence B, Gustafsson BI, Chan A, Svejda
B, Kidd M and Modlin IM: The epidemiology of gastroenteropancreatic
neuroendocrine tumors. Endocrinol Metab Clin North Am. 40:1–18.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirota S, Isozaki K, Moriyama Y, et al:
Gain-of-function mutations of c-kit in human gastrointestinal
stromal tumors. Science. 279:577–580. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heinrich MC, Corless CL, Duensing A, et
al: PDGFRA activating mutations in gastrointestinal stromal tumors.
Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hirota S, Ohashi A, Nishida T, et al:
Gain-of-function mutations of platelet-derived growth factor
receptor alpha gene in gastrointestinal stromal tumors.
Gastroenterology. 125:660–667. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Daniels M, Lurkin I, Pauli R, et al:
Spectrum of KIT/PDGFRA/BRAF mutations and
Phosphatidylinositol-3-Kinase pathway gene alterations in
gastrointestinal stromal tumors (GIST). Cancer Lett. 312:43–54.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reddy P, Boci K and Charbonneau C: The
epidemiologic, health-related quality of life, and economic burden
of gastrointestinal stromal tumours. J Clin Pharm Ther. 32:557–565.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miettinen M and Lasota J: Histopathology
of gastrointestinal stromal tumor. J Surg Oncol. 104:865–873. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robinson TL, Sircar K, Hewlett BR,
Chorneyko K, Riddell RH and Huizinga JD: Gastrointestinal stromal
tumors may originate from a subset of CD34-positive interstitial
cells of Cajal. Am J Pathol. 156:1157–1163. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ramage JK, Ahmed A, Ardill J, et al: UK
and Ireland Neuroendocrine Tumour Society: Guidelines for the
management of gastroenteropancreatic neuroendocrine (including
carcinoid) tumours (NETs). Gut. 61:6–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oberg K: Somatostatin-receptor mediated
diagnosis and treatment in gastrointestinal neuroendocrine tumours
(GEP-NET's). Rocz Akad Med Bialymst. 50:62–68. 2005.PubMed/NCBI
|
|
14
|
Klöppel G and Anlauf M: Epidemiology,
tumour biology and histopathological classification of
neuroendocrine tumours of the gastrointestinal tract. Best Pract
Res Clin Gastroenterol. 19:507–517. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schimmack S, Svejda B, Lawrence B, Kidd M
and Modlin IM: The diversity and commonalities of
gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch
Surg. 396:273–298. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hamilton SR and Aaltonen LA: World Health
Organization Classification of Tumors. Pathology and Genetics of
Tumours of the Digestive System. IARC Press. (Lyon). 2000.
|
|
17
|
Modlin IM, Moss SF, Oberg K, Padbury R,
Hicks RJ, Gustafsson BI, Wright NA and Kidd M: Gastrointestinal
neuroendocrine (carcinoid) tumours: Current diagnosis and
management. Med J Aust. 193:46–52. 2010.PubMed/NCBI
|
|
18
|
Klöppel GI, Couvelard A, Perren A, et al:
Mallorca Consensus Conference participants; European Neuroendocrine
Tumor Society: ENETS Consensus Guidelines for the Standards of Care
in Neuroendocrine Tumors: Towards a standardized approach to the
diagnosis of gastroenteropancreatic neuroendocrine tumors and their
prognostic stratification. Neuroendocrinology. 90:162–166. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oberg K and Castellano D: Current
knowledge on diagnosis and staging of neuroendocrine tumors. Cancer
Metastasis Rev. 30(Suppl 1): 3–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
George S and Desai J: Management of
gastrointestinal stromal tumors in the era of tyrosine kinase
inhibitors. Curr Treat Options Oncol. 3:489–496. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rabin I, Chikman B, Lavy R, Sandbank J,
Maklakovsky M, Gold-Deutch R, Halpren Z, Wassermann I and Halevy A:
Gastrointestinal stromal tumors: A 19 year experience. Isr Med
Assoc J. 11:98–102. 2009.PubMed/NCBI
|
|
22
|
Corless CL, Fletcher JA and Heinrich MC:
Biology of gastrointestinal stromal tumors. J Clin Oncol.
22:3813–3825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kang YN, Jung HR and Hwang I:
Clinicopathological and immunohistochemical features of
gastointestinal stromal tumors. Cancer Res Treat. 42:135–143. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
National Comprehensive Cancer Network
(NCCN): NCCN Clinical Practice Guidelines in Oncology. Soft Tissue
Sarcoma. v.2.2009 [Internet]. National Comprehensive Cancer Network
(Fort Washington, PA). 2009.
|
